24th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220184002 | TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 2022-06-16 |
20220184003 | Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2) - Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the same for use in the treatment of various conditions, and diseases, including diseases associated with demyelination. | 2022-06-16 |
20220184004 | IONIC CHANNEL MODULATION AS A METHOD FOR TREATING TUMORS THROUGH INFLAMMASOME ACTIVATION - The invention presents use of ion channel modulator to manipulate expression of the Tmem176b gene, also known as TORID (TOlerance Related and InduceD), to treat tumors. | 2022-06-16 |
20220184005 | HOMOTAURINE-ENRICHED COMPOSITIONS AND METHODS OF USE FOR ANIMAL HEALTH - The present disclosure generally relates to compounds comprising homotaurine that may be used in improving the general mental condition and/or general brain function of a non-human animal, and for the prophylaxis of chronic, aging-related mental deterioration in non-human animals. In addition, the present disclosure generally relates to compositions comprising homotaurine that may be used in determining whether a candidate veterinary compound and/or a candidate formulation can improve general mental condition and/or general brain function of animals and for the prophylaxis of chronic, aging-related mental deterioration in non-human animals. | 2022-06-16 |
20220184006 | COMBINATION THERAPY - The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof. | 2022-06-16 |
20220184007 | FORMULATIONS - Provided herein are high-dose formulations of acamprosate in a pharmaceutically acceptable salt form, as well as methods of preparing the same, and methods of using the same. | 2022-06-16 |
20220184008 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION - The present invention relates to a compound of Formula la, lb and Ic, (Formula Ia) a pharmaceutical composition comprising the same and their use in the treatment or prevention of pathological conditions associated to depolarizing GABAergic transmission including, for example, Down syndrome and autism. | 2022-06-16 |
20220184009 | PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY - Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation. | 2022-06-16 |
20220184010 | ANTIVIRAL COMPOSITIONS AND METHODS FOR INACTIVATING NON-ENVELOPED VIRUSES USING ALKYL 2-HYDROXYCARBOXYLIC ACIDS - The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition. | 2022-06-16 |
20220184011 | METHODS FOR TREATING CILIATED CAVITIES - A composition that can be used to treat a wide spectrum of gram positive and gram negative bacteria, including but not limited to those in biofilm form, can be used in cilia-containing areas such as the sinus cavities and middle/inner ear, while resulting in no, or very minimal amounts of, deciliation and/or loss of function (e.g., ability to clear material from the sinus cavity). Where such a targeted treatment area includes or might include a biofilm, the composition often can detach and assist in removing the biofilm from affected tissue. | 2022-06-16 |
20220184012 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY - Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent. | 2022-06-16 |
20220184013 | USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER - Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced. | 2022-06-16 |
20220184014 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE - Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of preparing the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders. | 2022-06-16 |
20220184015 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS ON BONE HEALTH - A method of improving and/or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy-inducing compounds. In one embodiment, the one or more autophagy-inducing compounds are selected from the group consisting of thymol, carvacrol, spermidine, urolithin (e.g., Urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5′ AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g. beta-hydroxybutyrate, ketone salts, or ketone ester derivatives), 4,4′-dimethoxychalcone and mixtures thereof. | 2022-06-16 |
20220184016 | BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS - Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component. | 2022-06-16 |
20220184017 | COMPOSITIONS FOR IMPROVING EYE HEALTH AND METHODS OF MAKING AND USING THEREOF - Some embodiments disclosed herein relate to a composition containing an effective amount of dietary nutrients. In some embodiments, ingestion of the composition provides one or more of the following benefits, or others, improved functioning of an environmentally stressed eye, increased tear flow from the lacrimal glands, improved quality of the lipid secretion from the meibomian glands (e.g., to improve tear breakup time), and augmented DHA fatty acid in the retina damaged by blue light. In some embodiments, the composition is configured to scavenge free radicals in the eye to prevent premature degradation of the visual functions. | 2022-06-16 |
20220184018 | OMEGA-3 FATTY ACID SUPPLEMENTATION FOR USE IN TREATING DRY EYE - This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement. | 2022-06-16 |
20220184019 | Use of chlorogenic acid in preparation of drug for preventing and treating ocular inflammation - Chlorogenic acid is used in the preparation of a drug for treating and/or preventing ocular inflammation. Chlorogenic acid can significantly alleviate symptoms of uveitis and scleritis, and has good treatment effects on ocular inflammation. | 2022-06-16 |
20220184020 | Polyphenols as Modulators of Platelet Function - Provided herein are methods of treating a vascular disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of a vascular disease associated polyphenol (e.g., rosmarinic acid), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of promoting or supporting vascular health in a subject, and methods of inhibiting platelet function (e.g., platelet aggregation) in a subject. | 2022-06-16 |
20220184021 | NOVEL FORMULATIONS COMPRISING MELFLUFEN - The invention provides a pharmaceutical formulation comprising (or consisting essentially of) the following components: i) melflufen, or a salt thereof; ii) propylene glycol; iii) optionally one or more physiologically acceptable aqueous solvent(s); and iv) optionally one or more additional therapeutic agent(s); or a pharmaceutical formulation comprising (or consisting essentially of) the following components: i) melflufen, or a salt thereof; ii) polyethylene glycol; iii) optionally one or more physiologically acceptable aqueous solvent(s); and iv) optionally one or more additional therapeutic agent(s). The invention also provides methods for preparing the pharmaceutical formulations of the invention, kits and uses of the pharmaceutical formulations of the invention. | 2022-06-16 |
20220184022 | DIETARY BUTYRATE | 2022-06-16 |
20220184023 | DICARBOXYLIC ACID ESTERS FOR INDUCING AN ANALGESIC EFFECT - The disclosure provides compositions and methods of inducing an analgesic effect. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester. | 2022-06-16 |
20220184024 | DICARBOXYLIC ACID ESTERS FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH PHOSPHOLIPASE D TOXIN - The disclosure provides compositions and methods of treating diseases and conditions associated with phospholipase D (PLD) toxin. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester. | 2022-06-16 |
20220184025 | NOVEL DEPSIDE DIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF - The present invention relates to novel depside dimeric compounds for improving skeletal muscle plasticity regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery. | 2022-06-16 |
20220184026 | COMPOSITIONS OF FULVIC ACID AND CANNABINOID AND USES THEREOF - Compositions with isolated fulvic acid in combination with a cannabinoid are disclosed herein. Also disclosed are methods of using said compositions for improving cellular regeneration, including the healing, treatment, or prevention of skin disorders. | 2022-06-16 |
20220184027 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND FOOD WITH FUNCTION CLAIMS - A DPP-IV inhibitor and a food with functional claims, which comprises methylated catechin as a novel active ingredient, are provided. | 2022-06-16 |
20220184028 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS - A method for treating or preventing amyotrophic lateral sclerosis (ALS) or other motor neuron disease in a subject, the method comprising administering to the subject a PKC activating compound (e.g., a bryostatin, such as bryostatin-1, or a bryolog) in a therapeutically effective amount to treat or prevent the motor neuron disease by activating PKC in the subject. The ALS may be, for example, classical ALS, primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and progressive bulbar palsy (PBP). The PKC activating compound may be administered at an initial loading dose of about 15, 24, or 48 micrograms weekly in the first one week or consecutive two or three weeks, followed by doses of about 12, 20, or 40 micrograms alternately every two or three weeks for at least 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, or 30 total weeks. | 2022-06-16 |
20220184029 | COMPOSITIONS AND METHODS FOR TREATING NEUROBLASTOMA - This disclosure relates to compositions and methods for treating a solid tumor, more specifically a neuroblastoma, in a subject in need thereof. | 2022-06-16 |
20220184030 | N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same - A composition comprising a combination of N-Phenylacetyl-L-prolylglycine ethyl ester and cannabidiol for oral administration to humans and other animals and a method for administering said composition are described. The composition provides synergistic nootropic benefits to the user, resulting in enhanced cognitive functions, such as increased focus, creativity, memory recall, and memory consolidation, among other cognitive functions. The composition generally does not cause side effects in the users and generally does not cause the user to develop tolerance to its nootropic effects. The composition optionally comprises a compound containing choline or a choline prodrug to supply choline to the brain of the user for the production of the neurotransmitter acetylcholine, and may also optionally comprise caffeine. | 2022-06-16 |
20220184031 | DUAL ANTAGONIST OF PGD2/DPR2 AND THROMBOXANE A2/TPR RECEPTORS AND USE FOR TREATMENT OF MALADAPTIVE IMMUNE RESPONSE OR THROMBOTIC DIATHESIS - The present invention relates to a pharmaceutical composition for treatment of a disease or condition characterized by or associated with stimulation of both DPr2 and TPr signaling, said composition comprising an effective amount of a dual receptor antagonist of DPr | 2022-06-16 |
20220184032 | INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES - The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity. | 2022-06-16 |
20220184033 | METHODS FOR PREDICTING AND REDUCING THE RISK OF PRETERM BIRTH - The present invention relates to a method for detecting specific proteins in amniotic fluid to predict the risk of preterm birth. The method determines different protein markers in premature amniotic fluid samples and normal amniotic fluid samples to predict the risk of preterm birth, and apply the expression levels of these protein markers to build a set of prediction models. This allows the medical staff to be prepared and greatly reduces the threat to the fetus. | 2022-06-16 |
20220184034 | METHODS FOR TREATING CUTANEOUS METASTATIC CANCERS - A method for treating a cutaneous metastatic cancer comprising administering tin ethyl etiopurprin (SnET2) to a subject suffering from a cutaneous metastatic cancer and exposing the subject at a pre-selected site with light at a wavelength and at a light dose sufficient to effect treatment to effect treatment. | 2022-06-16 |
20220184035 | HBV INHIBITOR AND ITS USE - The present invention provides anti-HBV compounds, pharmaceutically acceptable compounds or stereoisomers thereof, and preparation methods and uses for treating, eradicating or inhibiting HBV infection or for alleviating liver injury caused by HBV infection, and so on. | 2022-06-16 |
20220184036 | METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND) - In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND. | 2022-06-16 |
20220184037 | PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS - Methods for preventing or treating subjects having cancer based on the identification of pharmaceutical agents that target cancer stem cells (CSCs) have been identified. These methods include administering to the subject an effective amount of a COX2 inhibitor and an effective amount of a YAP1 inhibitor. In addition, methods of enhancing chemotherapeutic responses in cancer patients have been discovered and are described herein. | 2022-06-16 |
20220184038 | STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES - Encapsulated particles comprising one or more particle cores of silicon-containing material, wherein the one or more particle cores are encapsulated in a waxy lipid shell comprising: a) two lipidic components present at from 55% to 95% of the total encapsulated particle weight; b) a surfactant present at from 0.1% to 5% by weight of the total encapsulated particle weight; c) a co-surfactant present at from 0.01% to 1% by weight of the total encapsulated particle weight; d)a regulator of metastable state present at from 0.1% to 5% by weight of the total encapsulated particle, wherein the regulator of metastable state is selected from one or more of: the terpenes; the terpenoids; fatty acids, from myristic to docosanoic, pegylated by methyl ether of polyethylene glycol (PEG. Me M. W. 750-2000); diacylphosphatidylethanolamines pegylated with PEG;poloxamers (Pluronics); and derivatives thereof. Also related compositions and methods. | 2022-06-16 |
20220184039 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO - The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject. | 2022-06-16 |
20220184040 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE - The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of (S)-N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof. In certain embodiments of this method the malignant rhabdoid tumor is small cell cancer of the ovary of the hypercalcemic type (SCCOHT). | 2022-06-16 |
20220184041 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds - This application includes a compound of Formula I | 2022-06-16 |
20220184042 | FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal. | 2022-06-16 |
20220184043 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS - The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34 | 2022-06-16 |
20220184044 | USE OF RIFAXIMIN ON CIRCULATING AGED NEUTROPHILS IN SICKLE CELL DISEASE - Methods of treatment of sickle cell disease are based on the administration of the antibiotic compound rifaximin. | 2022-06-16 |
20220184045 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME - The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase and uses of the same in the treatment of c-kit kinase associated diseases. | 2022-06-16 |
20220184046 | METHODS OF ADMINISTERING ANTI-FIBROTIC THERAPY - The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders. | 2022-06-16 |
20220184047 | HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY - Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a thereapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a thereapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof. | 2022-06-16 |
20220184048 | ANTIBIOTIC COMBINATION THERAPIES - The invention provides antibiotic combination therapies for treating an | 2022-06-16 |
20220184049 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS - This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. | 2022-06-16 |
20220184050 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS - Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor. | 2022-06-16 |
20220184051 | FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS - Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations. | 2022-06-16 |
20220184052 | COMPOSITION COMPRISING FEXOFENADINE - The present disclosure provides a liquid formulation meant for nasal administration that includes fexofenadine or a salt or a hydrate or a solvate thereof. The compositions of the present disclosure may find utility in treatment of allergic conditions/diseases. The liquid formulation of the present disclosure gets converted into a gel upon its administration in the nasal region and releases the active agent locally in a sustained manner, while providing moisturizing effect and forming a layer on the nasal mucosa that acts like a barrier to entry of pathogens and allergens inhibiting their invasion into sinuses and deep layers of lining of the nose. Aspects of the present disclosure also relates to method of treating an allergic condition using the advantageous compositions of the present disclosure. | 2022-06-16 |
20220184053 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION IN MODERATELY SEVERE PATIENTS WITH PNEUMONIA - The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection. | 2022-06-16 |
20220184054 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS - Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor. | 2022-06-16 |
20220184055 | CHIAURANIB FOR TREATMENT OF SMALL CELL LUNG CANCER - Disclosed are a method for treating small cell lung cancer by using chiauranib and the use of chiauranib in the preparation of a drug for treating small cell lung cancer. | 2022-06-16 |
20220184056 | USE OF KDM5A GENE AND ATRX GENE - The present invention provides use of KDM5A gene and/or ATRX gene as biomarkers in evaluating the efficacy of Chiauranib or guiding the administration of Chiauranib, and use of Chiauranib for the manufacture of a drug for treating small cell lung cancer patients with gene mutations in KDM5A gene or ATRX gene. | 2022-06-16 |
20220184057 | COMBINATION TREATMENT OF OCULAR INFLAMMATORY DISORDERS AND DISEASES - The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent. | 2022-06-16 |
20220184058 | PHARMACEUTICAL COMPOSITION FOR TREATING AORTIC ANEURYSM - The present invention addresses the problem of providing a therapeutic agent for an abdominal aortic aneurysm, the therapeutic agent making drug therapy possible. | 2022-06-16 |
20220184059 | PROCESS FOR PREPARING SPHERICAL AGGLOMERATES OF TIMAPIPRANT - The present invention relates to a process for the preparation of spherical agglomerates of timapiprant; the invention also relates to spherical agglomerates of timapiprant obtained by the above process. | 2022-06-16 |
20220184060 | PHARMACEUTICAL COMPOSITION COMPRISING SPHERICAL AGGLOMERATES OF TIMAPIPRANT - The present invention relates to a process for the preparation of spherical agglomerates of timapiprant; the invention also relates to spherical agglomerates of timapiprant obtained by the above process and pharmaceutical formulation comprising said agglomerates of timapiprant. | 2022-06-16 |
20220184061 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 - Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. | 2022-06-16 |
20220184062 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE - The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814. | 2022-06-16 |
20220184063 | METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE - The invention provides methods of treatment of heart failure with hibernating myocardium using modified forms of trimetazidine, such as CV-8972 and CV-8814. | 2022-06-16 |
20220184064 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE - The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814. | 2022-06-16 |
20220184065 | METHODS OF TREATING NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY USING MODIFIED FORMS OF TRIMETAZIDINE - The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814. | 2022-06-16 |
20220184066 | CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR - This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m | 2022-06-16 |
20220184067 | MICROVASCULAR ANGINA - The invention provides means of diagnosing and treating microvascular angina (MVA). Diagnostic applications of intra-coronary guidewires are provided. Treatment of MVA patients with zibotentan is disclosed. The MVA patient can be identified and selected for treatment via the diagnostic applications provided. | 2022-06-16 |
20220184068 | METHODS OF TREATING HEART FAILURE BY ADMINISTERING OMECAMTIV MECARBIL - Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof. | 2022-06-16 |
20220184069 | METHODS OF TREATING SPLENOMEGALY - Therapeutic methods and pharmaceutical compositions for treating splenomegaly in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating splenomegaly using a BTK inhibitor. | 2022-06-16 |
20220184070 | LOW-DOSE TRIPLE COMBINATION FORMULATION - Pharmaceutical compositions useful in the treatment of metabolic disorders including diabetes, the compositions comprising a) a dipeptidyl peptidase IV (DPP IV) inhibitor such as sitagliptin, b) a biguanide such as metformin, and c) a sulfonylurea such as glimepiride, wherein each one of the DPPIV inhibitor, biguanide and sulfonylurea are at a dose that is at about 20-75% of the lowest diabetes therapeutic dose (LDTD). | 2022-06-16 |
20220184072 | METHODS OF TREATING NEUROPATHIC PAIN - The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment of neuropathic pain. | 2022-06-16 |
20220184073 | USE OF A H3R INVERSE AGONIST FOR THE TREATMENT OF SHIFT WORK DISORDER - The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder. | 2022-06-16 |
20220184074 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING A BRUTON'S TYROSINE KINASE INHIBITOR - The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods. | 2022-06-16 |
20220184075 | PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHING - The present invention relates to a pharmaceutical composition containing an HDAC6 inhibitor as an active ingredient for prevention or treatment of itching. The present invention provides a novel pharmaceutical composition containing, as an active ingredient, an inhibitor for inhibiting an HDAC6 enzyme, and thus can effectively inhibit and treat itching caused by trypsin, tryptase, histamine, antimycin A, chloroquine, or the like. | 2022-06-16 |
20220184076 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER - The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy. | 2022-06-16 |
20220184077 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS - Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor. | 2022-06-16 |
20220184078 | METHODS OF TREATING PROSTATE CANCER - The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I), | 2022-06-16 |
20220184079 | FORMULATIONS OF A COMPOUND MODULATING KINASES - Provided are solid dispersions of Compound I having the formula: | 2022-06-16 |
20220184080 | NEBULIZED IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF - The invention relates to nebulized imatinib formulations, manufacture, and uses thereof. | 2022-06-16 |
20220184081 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST - This invention relates to an antipruritic agent of formula (I) or (II), | 2022-06-16 |
20220184082 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND PEMBROLIZUMAB - The problem to be solved by the present disclosure is to provide a novel combination therapy using (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof, the combination therapy exhibiting an excellent antitumor effect on cancer patients with resistance to immune checkpoint inhibitors. The present disclosure provides an antitumor agent comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient, the antitumor agent being administered in combination with pembrolizumab to a cancer patient with resistance to immune checkpoint inhibitors. | 2022-06-16 |
20220184083 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS - Obesity is associated with low-grade inflammation in adipose tissue (AT) and dysfunctional adipocytes producing inflammatory molecules. A recent study reveals profound MAIT cell abnormalities inpatients harboring metabolic disorders, suggesting their potential role in these pathologies. Now the inventors show that MAIT cells induce adipose tissue and ileum dysfunction and inflammation in obese mice. Moreover, the inventors show that a treatment with an agent capable of inhibiting the activation of MAIT cells (i.e. Ac-6-FP) during high fat diet (HFD) improved metabolic parameters and in particular insulin sensitivity. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of obesity and obesity-related disorders. | 2022-06-16 |
20220184084 | COMPOSITIONS AND METHODS FOR TREATING CUSHING'S DISEASE - Disclosed herein are methods of treating a disease or disorder characterized by an increased secretion of adrenocorticotropic hormone (e.g., Cushing's disease). Also disclosed herein are methods of identifying compounds for use in treating said diseases or disorders. | 2022-06-16 |
20220184085 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING TLR7 AGONIST - A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties. | 2022-06-16 |
20220184086 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER - Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase-1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels. | 2022-06-16 |
20220184087 | METHODS AND COMPOSITIONS RELATING TO TREATMENT OF CANCER - According to aspects of the present disclosure, methods and compositions are provided which relate to treating cancer in a subject in need thereof, including: administering 1) an anti-cancer immune therapeutic agent, and 2) a stimulator of p53 levels and/or p53 activity, as a combination formulation or separately, thereby increasing levels and/or activity of p53, and activating NK cell activity in the cancer, providing therapeutic benefits, converting a “cold tumor” into a “hot tumor” leading to a TME responsive to immunotherapy via tumor cell recognition and killing that is not dependent on T-cell mediated immunity. | 2022-06-16 |
20220184088 | USES OF DPP IV INHIBITORS - The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments. | 2022-06-16 |
20220184089 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES - Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H | 2022-06-16 |
20220184090 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE - The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments. | 2022-06-16 |
20220184091 | Methods of Treating Cancer with Chk1 Inhibitors - Disclosed herein are methods of treatment by administering SRA737 as a monotherapy or in a combination therapy that is useful for treating patients with cancer. | 2022-06-16 |
20220184092 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS - Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor. | 2022-06-16 |
20220184093 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS - Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor. | 2022-06-16 |
20220184094 | HYDROCHLOROTHIAZIDE COMPOSITIONS - Disclosed herein is a powder for oral suspension and a reconstituted product therein comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema. | 2022-06-16 |
20220184095 | MELOXICAM CO-CRYSTAL COMPOSITIONS - The solubility and bioavailability properties of meloxicam can be improved by preparing compositions of meloxicam co-crystals and reducing the particle size of (e.g., “nanosizing”) co-crystals. Such compositions with improved dissolution pharmacokinetic properties can be prepared by granulation and blending the co-crystals with extragranular excipients to provide oral solid dosage forms. As a result of the improved properties of the meloxicam oral dosage forms, the compositions may be useful for the treatment of pain, including acute pain. | 2022-06-16 |
20220184096 | APPLICATIONS OF IMINOSTILBENE IN TERMS OF PREVENTING AND TREATING CARDIAC CEREBRAL ISCHEMIA/REPERFUSION INJURY - Applications of iminostilbene in preparing a medicament for treating a cardiovascular disease, specifically, cardiac cerebral ischemia/reperfusion injury. Iminostilbene is capable of reducing three myocardial enzymes and inflammatory factors during ischemia reperfusion and reduces apoptosis during ischemia reperfusion. | 2022-06-16 |
20220184097 | BETULIN-CONTAINING BIRCH BARK EXTRACTS AND THEIR FORMULATION - The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical corn-positions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing. | 2022-06-16 |
20220184098 | TREATMENT OF NF-KB-MEDIATED DISEASE - The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof. | 2022-06-16 |
20220184099 | METHODS OF USING OBETICHOLIC ACID - The disclosure relates to methods of using obeticholic acid or pharmaceutically acceptable salt or amino acid conjugate thereof for slowing down or reversing the progression of compensated cirrhosis. | 2022-06-16 |
20220184100 | ENHANCED D VITAMIN NUTRACEUTICAL COMPOSITIONS AND METHODS FOR MAKING AND USED SAME - D vitamins enhanced nutraceutical compositions including one or more UV light treated, dried, and comminuted fungus materials and nutraceutical compositions including one or more UV light treated, dried, and comminuted fungus materials and one or more dried and comminuted herb materials and methods for making and using same. | 2022-06-16 |
20220184101 | PARASITE THERAPY - There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate. | 2022-06-16 |
20220184102 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION - Provided are chemically modified tetracycline (CMT) derivatives for the treatment of non-exudative macular degeneration. The CMT derivatives lack antimicrobial activity, include a phenol ring, and a chemical structure sufficient to chelate Zn2+. Methods of inhibiting and/or minimizing inflammation in a subject, including administering to the subject a dose of a CMT derivative, are also provided. Methods of treating non-exudative age-related macular degeneration (AMD) are provided. | 2022-06-16 |